Baylin was among 489 AAAS members and four from
Baylin is an international leader in the field of epigenetics, which studies biochemical changes to the environment of DNA, rather than changes directly to it. These changes can alter gene expression and facilitate cancer origination and growth. He is among the most frequently cited physician-scientists in epigenetics. His laboratory studies in lung cancer and leukemia helped lead to clinical trials of the first demethylation agent, 5-azacytidine, and to its FDA approval in a preleukemic condition known as myelodysplastic syndrome. His research also ushered in other epigenetic therapies.
An announcement of the new fellows will be published in the New & Notes section of the journal Science on
Contact:
Tel: 410-502-9422
Email: hjones49@jhmi.edu
(C) 2020 Electronic News Publishing, source